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CObjective: To provide a comparison of national drug reimbursement deci-
sion-making, includinganupdateof economic evaluation roles andbarriers,
in Thailand, China, and South Korea. Methods: Documentary reviews
supplemented by experiences of policymakers. Results: National health
nsurance policy in all the three countries has been developed toward
overage for all. It leads to higher health-care expenditures and requires a
ood reimbursement system for health-care services, including drugs.
rug reimbursement decision-making in these countries is to develop a
eimbursement list with the help of various committees having different
oles. Primarily, they assess the clinical and safety evidence. Economic
vidence, including budget impact and pharmacoeconomic evaluation,
as also been very important for their reimbursement decision-making.
his evidence is sometimes used in negotiation mechanism, which al-
ows pharmaceutical companies to lower their drug prices and leads to O
O
i
e no
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al So
doi:10.1016/j.jval.2011.11.002ower overall drug expenditures. Several common barriers, for example,
uman capacity and data availability, for obtaining economic evidence in
ll the three countries, however, still exist. Conclusions: Drug reim-
ursement decision-making in Thailand, China, and South Korea is in its
ransition period. It seems to run in the same direction, for example,
uidelinedevelopment andpharmacoeconomic evaluation agency estab-
ishment. Pharmacoeconomic evaluation plays important roles in the ef-
ciency of drug reimbursement decision-making, even though there are
everal barriers to be overcome.
eyword: drug reimbursement, health insurance, reimbursement deci-
ion-making.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Health-care systems in the Asia-Pacific region have dramatically
changed in the last 10 years. One of the major changes among
countries in the region has been health insurance coverage.While
their health insurance systems have aimed for an increase in ac-
cess to health-care services, health-care policymakers need to en-
sure efficient resource allocation because of limited resources.
These countries have established their own evidence-based
mechanisms for making decisions in various processes, for exam-
ple, approval and utilization of health technologies [1,2]. Among
these processes, drug reimbursement is one of the most powerful
tools formulated by policymakers because it financially affects
providers and, in turn, could affect patients. It is a complex issue,
however, because it always has two facets, increasing and restrict-
ing access. Therefore, this topic was chosen to be presented at the
first plenary session of the ISPOR 4th Asia-Pacific Conference in
Phuket, Thailand, on September 6, 2010. Thailand, China, and
South Korea were selected as country examples because they had
rapidly changing systems in the region. Senior policymakers were
invited to represent their countries and were asked to review the
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drugs. This commentary was synthesized from this specific ple-
nary session and aimed to provide a comparison of national drug
reimbursement mechanisms, including an update of economic
evaluation roles and barriers, across all the three countries.
Health insurance systems
Drug reimbursement mechanisms are part of health insurance
systems. Thailand, China, and South Korea have their own unique
health insurance systems, which tend to shape the reimburse-
mentmechanismbecause of several factors, for example, employ-
ment type, source of funding, and payment mechanism.
Thailand
Thailand has approximately 64 million people and had a gross
national income (purchasing power parity) of approximately
180,000 Thai baht per capita in 2008 (approximately US$5000) [3].
n average, Thai citizens spent approximately 4% of their annual
ncome for health-care services. The country is one of the Asia-
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Major changes in national health insurance began in 2002, when a
Universal Coverage (UC) health insurance policy was launched.
Since then, the health insurance system in Thailand has three
major schemes, the Civil Servant Medical Benefit Scheme
(CSMBS), the Social Security Scheme (SSS), and the Universal Cov-
erage (UC) scheme. The UC scheme covers about 75% of the coun-
try’s population while the CSMBS and the SSS cover approxi-
mately 22%. Therefore, only about 2% of the whole population is
still uninsured [1]. The CSMBS was established as a fringe benefit
in 1978, to provide health-care services to all government employ-
ees, their dependents, and retirees. It is fully funded by general
tax, and it is operated by the Comptroller General’s Department,
Ministry of Finance. The SSS was established in 1990, and it is a
compulsory insurance scheme for employees in the private sector.
It covers only the employees themselves. Its source of funds basi-
cally comes fromemployees, employers, and the government, and
it is run by the Social Security Office (SSO). The UC scheme is a
social welfare scheme by nature for people who are not eligible for
the CSMBS and the SSS. It is primarily funded by general tax, and
it is operated by the National Health Security Office [1].
China
China has systematically carried out a series of reforms inmedical
security since 1990s. Now a multilevel medical security system,
which is compatible with the socialist market economy of China,
has been established. It plays an important role in securing and
improving people’s lives and stabilizing the social stability in
China. Basically, there are three principal medical insurance
schemes, Urban Employee Basic Medical Insurance, Urban Resi-
dent Basic Medical Insurance, and New Rural Cooperative Medical
Care. For disadvantaged groups, Urban and Rural Social Medical
Aid is also provided as a minimum security. Moreover, there are
other supplementary schemes, including Enterprise Supplemen-
tary Medical Insurance, Commercial Health Insurance, Civil Ser-
vants Medical Subsidy, and Medical Security, for specific groups.
The Urban Employee Basic Medical Insurance scheme, launched
in 1998, covers urban employees and retirees, some urban resi-
dents with flexible employment, and rural migrant workers. In
2003, the Chinese government began to establish the New Rural
Cooperative Medical Care scheme for rural residents while the
Urban Resident Basic Medical Insurance scheme was initiated in
2007 to provide medical benefits to all urban residents, excluding
those covered by the Urban Employee Basic Medical Insurance
scheme. In some cities, the Urban Resident Basic Medical Insur-
ance and New Rural Cooperative Medical Care schemes have been
integrated into a unified scheme named the Urban & Rural Resi-
dent Basic Medical Insurance scheme. In 2009, the total medical
insurance coverage rate in China reached 93%, with Urban Em-
ployee BasicMedical Insurance scheme insuring 17% (220million),
the Urban Resident Basic Medical Insurance scheme insuring 14%
(180million), and theNewRural CooperativeMedical Care scheme
insuring 61% (830 million) of the residents.
South Korea
Korean National Health Insurance (KNHI) was introduced as the
first social insurance program for only corporate employees in
1977, and it covered the whole population of the Republic of Korea
in 1989. Basically, the KNHI is funded by various sources, including
premium, co-payment, tax, and employment funds. Fee-for-ser-
vice is the major payment method of the KNHI while the diagnos-
tic related group (DRG) method is used for seven types of medical
procedures. Similar to any fee-for-service type of payment system,
overutilization is a challenge for the KNHI. In 2009, the benefit
coverage rate (rate of reimbursement for covered services) for in-
patient care was approximately 80% and for outpatient care wasbetween 50% and 70%. There are various agencies in South Korean
health-care system. For overall administration, the Ministry of
Health and Welfare controls the KNHI program. While medical
care institutions provide medical care, an agency called the Na-
tional Health Insurance Corporation (NHIC) is responsible for re-
imbursement to health-care provider institutions. In addition, the
Health Insurance Review and Assessment service (HIRA), which is
a specialized governmental organization, is responsible for health
insurance review and assessment processes. In these processes,
medical care institutions need to submit claims to HIRA. HIRA
then checks the input and error of claims, and the claims undergo
an indicator review. The results of the review are eventually trans-
mitted to the NHIC and provider institutions.
Even though these three countries have unique health insur-
ance systems, they have developed toward universal coverage,
which extensively increases access to health-care services, in-
cluding drugs. The universal health insurance coverage, however,
can be expensive, especially drug expenditure, if the reimburse-
ment has not been set appropriately.
Drug reimbursement systems
Drugs are what patients expect when they obtain health-care ser-
vices. The drug reimbursement system itself has two facets be-
cause it can not only contain costs but also limit access. Therefore,
the reimbursement system in each country has been carefully de-
signed, especially the list of reimbursable drugs. Table 1 summa-
izes drug reimbursement systems across all the three countries.
Thailand
In Thailand, all three major insurance schemes have their own
health service benefit packages listing reimbursable services and
also have their own payment systems. Basically, the benefit pack-
ages are composed of two major health services, ambulatory and
inpatient services, under different kinds of reimbursement meth-
ods. The CSMBS uses prospective payment (DRG) for inpatient ser-
vices and fee-for-service type of payment for ambulatory services.
It limits its beneficiaries to obtain any services only in public hos-
pitals. While the SSS allows its beneficiaries to use health-care
services at either public or private network hospitals, basically its
payment type is capitation for both inpatient and ambulatory ser-
vices. Similar to the CSMBS, the UC scheme provides similar cov-
erage for inpatient health services under theDRG type of payment.
It applies capitation type of payment, however, for ambulatory
services [1].
Because the nature of provided inpatient services depends to a
large degree on common medical and nursing procedures, the
DRG for the CSMBS and the UC scheme and capitation for the SSS
work efficiently. The DRG has been set for each health-care proce-
dure or intervention, and the CSMBS and the UC scheme can allo-
cate their resources accordingly. The SSS beneficiaries may some-
times suffer with the underutilization of provided services that
could possibly happen from capitation. Its impact tends to be mi-
nor becausemost beneficiaries are in theirworking ages and rarely
use the inpatient services. Recently, however, the SSS beneficia-
ries have raised a concern that their health benefit package is
inferior to that offered by the CSMBS and the UC scheme. The
ambulatory services rely heavily on prescription drug use. Deci-
sions for drug reimbursement have a longer history, and it has
been more systematically developed than other areas in health-
care services. The mechanisms, processes, evidence used in deci-
sions for drug reimbursement, and the role of health technology
assessment on drug reimbursement in Thailand have been com-
prehensively presented in previous literatures [1,4]. Basically, the
National Drug Committee develops the National List of Essential
Medicines (NLEM), which is a list of drugs, vaccines, radioactive
Table 1 – Comparison of drug reimbursement decision-making system across three countries.
Thailand China South Korea
Structure: Organizations involved in developing
the reimbursement list
● Central government agency ● Ministry of Public Health ● Ministry of Human Resources and Social
Security and other related ministries
● Ministry of Health and Welfare
● Government authorities/committee ● Food and Drug Administration (FDA) ● Provincial authorities ● Health Insurance Review Agency (HIRA), e.g.,
Drug Benefit Coverage Assessment Committee
(DBCAC)
● Health Intervention and Technology
Assessment Program (HITAP) ● National Health Insurance Cooperation (NHIC)
Process: Development of the reimbursement list Steps Steps Steps
● Industry submission of application ● Clinical benefit and safety assessment ● Industry submission of application
● Clinical benefit and safety assessment ● Pharmacoeconomic evaluation and budget
impact analysis
● Clinical benefit and safety assessment
● Pharmacoeconomic evaluation and
budget impact analysis
● Professional groups review and preliminary
list formed
● Pharmacoeconomic evaluation and budget
impact analysis
● Price negotiation ● More than 2000 experts voting ● Price negotiation
● Getting approval from ministry ● Suggestion of reimbursement limitation ● Getting approval from ministry
Decision-making criteria
Decision-making criteria ● Clinical benefit
● Safety and efficacy score and cost
index
● Getting approval from ministry ● Cost-effective threshold, e.g., GDP per capita for
each quality-adjusted life-year
● Cost-effective threshold, e.g., gross
domestic product (GDP) per capita for
each quality- adjusted life-year
● Budget impact
Decision-making criteria
● Safety, efficacy, and clinical needs
● Information of price and pharmacoeconomic
evaluation in other countries
● Budget impact
● Reimbursement status and price in other
countries
● Budget impact
Outcome: Reimbursement list National List of Essential Medicines
(NLEM)
National Basic Medical Insurance Drug
Formulary List
Positive List System
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S123V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 1 2 0 – S 1 2 5substances, and disinfection agents that are necessary for the pre-
vention and treatment of all major health problems, to encourage
rational drug use. It also works as a reimbursement list for all the
three schemes. The Food and Drug Administration (FDA), under
the authority of the Ministry of Public Health, plays an important
role—the selection of individual experts or institutions across the
country to work for the NLEM committee. Primarily, the NLEM
committee is composed of two major groups—clinicians and
health economists in several subcommittees. While the clinicians
assess the clinical benefits and safety of all drugs by using the
developed safety and efficacy score, and the cost index, the health
economists evaluate some products. Finally, the NLEM committee
collects all the evidence and endorses the list.
The current practice of drug reimbursement decision-making
in Thailand has been drastically changed in the past few years,
and it is still very dynamic. Under limited resources, the practice
has recently been based on pharmacoeconomics (PE) because it
helps the Thai government make rational policies or allocate re-
sources efficiently. PE has been applied in the decision process on
the reimbursement of drugs listed on the NLEMwith clear institu-
tional structure, capacity, and functions [1]. A health technology
assessment agency under the Ministry of Public Health, Health
Intervention Technology Assessment Program (HITAP), is primar-
ily responsible for conducting economic evaluation of some drugs,
especially expensive ones. Its major mission is to efficiently and
transparently appraise health interventions and technologies. Ev-
ery year HITAP asks various stakeholders, for example, health-
care providers, academicians, payers, and patient advocacy
groups, across the country for potential drugs that should be eval-
uated. After the list of these drugs is finalized, HITAP assigns its
own scientists to conduct economic evaluation. HITAP developed
not only a national guideline for economic evaluation but also
agreed with theWorld Health Organization guideline that average
GDP per capita be considered as a cost-effective threshold. Some-
times, the results of economic evaluation show that particular
drugs have higher cost per quality-adjusted life-years gained than
the threshold; the evidence has been used to successfully negoti-
ate drug prices with manufacturers before the drugs are listed on
the NLEM.
Currently, the Thai FDA is developing a new NLEM. Pharma-
ceutical companies have been asked to voluntarily include PE in-
formation in their submitted dossiers for being listed in the NLEM.
The economic evidence that the health economic working group
members consider, however, is not only the PE but also budget
impact analysis. Both of them help policymakers make better de-
cisions on resource allocation and budgetmanagement. The phar-
maceutical companies have also been more active in the prepara-
tion of the PE information. If they can prove that their drugs are
cost-effective, as compared to those of their competitors, the PE
information would be a surplus of the drugs and increase the
chance of their being listed on the NLEM.
There have been several barriers for using the PE information
in reimbursement decision-making. First, similar to other coun-
tries in the Asia-Pacific region, Thailand still lacks PE experts. Even
though the current situationhas been better than itwas in the past
several years, the experts in this area are still in demand. This
problem led to another barrier, which is the transparency ques-
tion. This transparency barrier works both ways for the Thai gov-
ernment and the pharmaceutical companies. While the govern-
ment has a major concern on the validity of the PE information
submitted by the industry, the pharmaceutical companies usually
complain about the transparency of the PE information consider-
ing process. The companies also have a concern that the govern-
ment would focus more on prices or expenditures than on the PE
information and therefore are reluctant to invest in obtaining the
PE information locally because the drug market in Thailand is rel-
atively small. Recently, there has been a suggestion that thirdparty or external experts should be hired to audit the PE informa-
tion. Because the number of experts in this area is small, this
suggestion seems to be unrealistic.
The cost-effective threshold has become a critical barrier for
adopting PE. The national guideline for economic evaluation de-
veloped by HITAP adopted theWorld Health Organization sugges-
tion for the cost-effective threshold, and it has been applied to the
development of the NLEM. Only those drugs that have a cost per
quality-adjusted life-year gained below the averageGDPper capita
are considered cost-effective drugs [1]. Recently, the Thai GDP per
capita has been less than 180,000 Thai baht (approximately
US$5000), and this threshold is usually applied across the board.
Noticeably, a number of products, especially anticancer treatment
and biological drugs, tend to be not cost-effective if this threshold
is used. Some of them, however, were sometimes proved to be
cost-effective for particular patient groups and were listed in the
NLEMwith recommendations. These recommendationswere usu-
ally found violated. Therefore, an auditing system for expensive
drugs has been used for the CSMBS and the UC scheme reimburse-
ment process to ensure rational drug uses and to control costs.
Another major barrier of using the PE is the availability of nec-
essary and relevant data. Even though data became more impor-
tant for the health-care decision-making in Thailand, they are
fragmented and gradually developed. Not only the comprehen-
sion of data but also their validities are still problematic. Only little
health-care data are available at the national level, and most of
them are for administrative purposes. The prospective price list of
DRG is an example and has been used in a number of PE studies.
Recently, data at the patient level have become more focused. In
reality, most government hospitals have their own electronic pa-
tient records, which are primarily used for administrative pur-
poses. Data sharing is very restricted because of major concerns
about confidentiality. Therefore, primary data needed to be col-
lected in most of previous PE studies. Generally, the pharmaceu-
tical companies can hardly access patients’ records collected by
the government hospitals. Unlike conducting clinical trials, the
industry has been reluctant to invest in collecting data for PE stud-
ies. It is concerned about how seriously the Thai government uses
the PE evidence in its decision-making. Also, the pharmaceutical
market in Thailand may not be large enough for the pharmaceu-
tical companies to invest in this relatively new area. Frequently,
the pharmaceutical companies have brought resources, including
data, models, and experts, from their regional or headquarter of-
fices. Only recently, local capacity has been built in several com-
panies.
China
Formulary is an accepted management of drugs for health insur-
ance in China. Drugs listed in the formulary should be clinically
needed, safe and effective, convenient to use, and reasonably
priced and should have sufficient market supply. They must also
meet some basic criteria, for example, listing in the Pharmacopoeia
of the People’s Republic of China (current edition), andmeet the stan-
dard of the State FDA. Similar to other countries, imported drugs
need to get approvals from the State FDA.
National, provincial, and local authorities have their own re-
sponsibilities in the formulary-making and implementing pro-
cess. A primary reimbursement formulary in China is the National
Basic Medical Insurance Drug Formulary List. It is codeveloped by
the Ministry of Human Resources and Social Security and other
relatedministries. TheNational BasicMedical InsuranceDrug For-
mulary List is composed of three parts, which are Western medi-
cines, traditional Chinese medicines, and Chinese herbal pieces.
They are handled differently in the reimbursement list. The posi-
tive reimbursement list is used for Western medicines and tradi-
tional Chinese medicines; on the other hand, the negative reim-
bursement list is applied to Chinese herbal pieces. Also, some
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mals and animal organs, dried fruits and liquid preparations
brewedwith traditional Chinesemedicines, fruit preparations and
oral effervescent agents, blood products, protein products (except
special indications, first aid, and emergency treatment), are not
included.
Drugs in the positive reimbursement list have been divided
into two classes, A and B, from several aspects, such as drug char-
acteristics, authorization level, reimbursement rates, and usage
limitation. Generally, drugs in class A are essential with broad
applications, have good effects, and have lower prices, while those
in class B are optional, have good effects, and have relatively
higher prices. Drugs in class A are allowed to be reimbursed at
specific rates with few limitations, while the costs of drugs in class
B must be shared as co-payment by the insured.
The development of the drug formulary follows precise proce-
dures. The first is to collect and compare drug data comprehen-
sively. On the basis of all drugs approved officially in a certain
period, experts review and consider their clinical benefits, price
information, safety data, and international PE data. They then en-
ter the second step, PE. In this step, pharmacoeconomists not only
compare the drugs under pharmacoeconomic views andmethods
but also analyze the impact of these drugs on the funds ofmedical
insurance, work injury insurance, and maternity insurance. Only
thosewith pharmacoeconomic advantages and optimal impact on
the funds are selected. All information is reviewed and discussed
by professional groups to reach a consensus before a preliminary
formulary is formed. The next step is voting, which is deployed at
both national and provincial levels. More than 2000 experts are
involved in this process. On the basis of voting results, consulta-
tion experts bring forward payment limitation suggestions to
some drugs, which are expensive and abused easily. Finally, after
related ministries consolidate and examine all the information
and suggestions, they approve the formulary and then dissemi-
nate it. Since initiating national health insurance reforms in 1998,
China has promulgated three versions of the drug formulary,
which are State Basic Medical Insurance Drug Formulary (2000
version), State BasicMedical Insurance andWork Injury Insurance
Drug Formulary (2004 version), and State Basic Medical Insurance,
Work Injury Insurance, and Maternity Insurance Drug Formulary
(2008 version). There have been great expansions in drug types
and numbers. In the 2000 version, the formulary contained 725
Westernmedicines and 415 Chinesemedicine preparations. In the
latest version, the State Basic Medical Insurance, Work Injury In-
surance, and Maternity Insurance Drug Formulary issued in 2009,
the drug numbers increased to 1164 and 987 for theWesternmed-
icines and Chinese medicine preparations, respectively. This re-
flects higher medical scientific progress, greater insurance pay-
ment capacity, and more extensive benefit coverage.
To give priority to the basic health needs of the population,
China developed the National Essential Medicines List for Primary
Healthcare Facilities. The most recent (2009) National Essential
Medicines List for Primary Healthcare Facilities includes 307
items. Basically, these drugs must have higher levels of clinical
benefits and safety with low costs. In addition, the central govern-
ment allows the provincial governments to addmore drug items if
local needs exist. All drugs listed at the national and provincial
levels are included in class A of the National Basic Medical Insur-
ance Drug Formulary List to improve affordability and access to
essential drugs.
Recently, another round of health system reforms in China has
started, and it is aimed at developing basic medical insurance for
all citizens. The reform has three primary objectives. The first ob-
jective is to consolidate and expand basic health insurance cover-
age. Specifically, the insured population of Urban Employee Basic
Medical Insurance needs to reach 410 million and the coverage
rate of New Rural Cooperative Medical Care needs to stabilize at90%. The second objective is to reinforce and balance basic medi-
cal insurance benefits. The subsidy for citizens to enroll in New
Rural Cooperative Medical Care or Urban Resident Basic Medical
Insurance would be raised to 120 renminbi (RMB) per year per
capita. The reimbursement rate of inpatient expenditures covered
by Urban Resident Basic Medical Insurance or New Rural Cooper-
ative Medical Care would be more than 60%. The third objective is
to improve basicmedical insurance fund administration. Prospec-
tive paymentmethods, especially capitation and paying according
to diagnosis and global budget, are encouraged. The negotiation
mechanism between medical insurance agencies and medical
care and drug providers is also to be explored.
As a consequence of these reforms, drugmanagement inmed-
ical insurance has been developed. PE is encouraged to be
strengthened for use in the process of new drug approval and
pricing. The exploration of a negotiation mechanism for drugs
listed in the National Basic Medical Insurance Drug Formulary is
suggested. Both national and local insurance agencies should
work together to organize the negotiation team. The PE of clini-
cally needed and expensive drugs with innovation and unlisted in
the National Basic Medical Insurance Drug Formulary should be
ready for the negotiation mechanism. Similar to many countries
in the Asia-Pacific region, however, China needs to overcome
some barriers to strengthen PE, including the number of phar-
macoeconomists, comprehensive and valid database of drug price
information, safety, professional agencies, and training. It is rec-
ommended that pharmaceutical companies provide the relevant
data and participate in the negotiation process. Independent re-
view experts will be in charge of submitting review proposals,
checking data, and also conducting PE.
South Korea
Total health-care expenditure in South Korea has been increasing
as in other countries. By 2009, as the need for health-care services
continued to grow, the total expenditure was almost three times
the total expenditure for 2001. The rapidly increasing health ex-
penditure has created a greater requirement for proof of “value for
money” in the approval and funding of newmedical technologies.
Consequently, the South Korean government introduced the Pos-
itive List System in December 2006. Overall, the purpose of the
Positive List System is to maximize the cost-effectiveness of drug
use for health insurance benefit. The Positive List System selects
drugs that are effective in both therapeutic and economic aspects
for health insurance benefit coverage. Reimbursement and price
decisions for new drugs are separated. HIRA is responsible for
reimbursement assessment while the NHIC conducts price nego-
tiations with pharmaceutical companies. In the Positive List Sys-
tem, the pharmaceutical company voluntarily submits applica-
tions for new drugs. The government opens the pathway to list
necessary drugs by the authority of the Minister of Health and
Welfare when needed. HIRA is also in charge of reviewing the
reimbursement status of listed drugs. It regularly excludes drugs
neither produced nor claimed for 2 years and reevaluates clinical
benefits and the price of drugs that were listed before the Positive
List System was introduced.
After a pharmaceutical company submits an application for a
new drug to HIRA, HIRA performs an economic evaluation and
assesses the appropriateness of the benefit of inclusion of the
drug. These are done by working level and the Drug Benefit Cov-
erage Assessment Committee (DBCAC) in HIRA. Based on HIRA’s
assessment results, the NHIC negotiates with the pharmaceutical
company for pricing. If the negotiation fails, drugs are not placed
on the list. Nevertheless, there is a Drug Reimbursement Coordi-
nation Committee that mediates necessary drugs that can be re-
imbursed. Finally, the Minister of Health and Welfare publishes
the final price to the public after review by the Health Insurance
Policy Review Committee within the ministry.
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resentatives of the Korean FDA, consumers, medical experts, and
HIRA. Under the DBCAC, as a subcommittee, HIRA has an eco-
nomic subcommittee composed of five members, two medical,
one statistical, and two health technology experts. This subcom-
mittee reviews the appropriateness of the economic model and
the cost-effectiveness. HIRA itself also has two clinical advisory
committees, the Healthcare Review and Assessment Committee
and the Serious Illness Review Committee. The Healthcare Review
and Assessment Committee is a group of medical specialists who
advise on the medical feasibility and coverage restriction while
the Serious Illness Review Committee is composed of some spe-
cialists from the Korean FDA, medical experts, and specialists
fromHIRA and is in charge of advising on coverage restrictions for
drugs prescribed to patients with cancer. For the Positive List Sys-
tem, there are five criteria for decision-making—clinical benefits,
cost-effectiveness results, impact on health-care budget, reim-
bursement status and prices in other countries, and potential im-
pact on other aspects of public health. There are, however, some
exceptions. These are collectively known as “rules of rescue,”
which are no alternative treatments, no alternative drugs for se-
vere or life-threatening diseases, and drugs for rare diseases and
necessary to treat these patients.
It is mandatory to submit PE evidence on new medicines to
prove their cost-effectiveness for the purpose of reimbursement. If
a pharmaceutical company wants to launch a new drug with im-
proved effectiveness butwith a higher price comparedwith that of
amain comparator, it has to submit the cost-effectiveness or cost-
utility analysis of the drug to be reimbursed. In this case, incre-
mental cost-effectiveness ratio is a central criterion for the reim-
bursement decision. HIRA does not have an explicit incremental
cost-effectiveness ratio threshold. It will be accepted or rejected,
however, in reference to GDP per capita, considering the incre-
mental cost-effectiveness ratio in regard to disease severity, soci-
etal burden, quality of life, and innovations. For this process, HIRA
developed assessment guidelines such as the Pharmacoeconomic
Evaluation Guideline, Submission Guideline, and the DBCAC as-
sessment criteria. Also, HIRA provides Presubmission Consulting
Services and opens the assessment results to the public on its
homepage (www.hira.or.kr) where assessment content, sched-
ules, and related references can be found. In addition, HIRA pro-
vides information such as the annual average weighted price of
individual ingredients and claims data. Regular education pro-
grams about any change in guidelines and laws for companies are
also provided.
HIRA has excluded drugs that have not been produced or
claimed for 2 years since the Positive List System was introduced.
Consequently, listed drugs have decreased from 20,775 items in
2006 to 15,091 items in 2010. HIRA performed a “Reevaluation of
listed drugs” to review the reimbursement status of drugs that
were listed before the Positive List System by the therapeutic
groups. The therapeutic groups of the pilot project were migraine
and hyperlipidemia, and 378 drugs were reviewed. As a result, 239
drugs were maintained, 128 drugs had prices lowered, and 11
drugs were excluded from the list. Overall, after the Positive List
System was introduced, the annual growth rate of drug expendi-
ture decreased from 14.6% during 2001 and 2005 to 11.5% during
2007 and 2009.
As in Thailand and China, PE demands much time and great
efforts. Lack of relevant evidence such as local costing data and
head-to-head randomized controlled trials with relevant compar-
ators presents a challenge. For instance, relevant local cost datawere used in about 60%of submissions and randomized controlled
trials comparing directly with comparators were used in 64% of PE
submissions. Various efforts are being made to overcome these
barriers. For instance, the development of guidelines for conduct-
ing indirect treatment comparison is under active discussion in
South Korea. The revision board of the guidelines for PE is cur-
rently gathering the opinions from pharmaceutical companies.
Conclusions
In conclusion, drug reimbursement decision-making in Thailand,
China, and South Korea is in its transition period; however, all the
three countries have a similar structure, process, and outcome.
Also, they seem to run in the same direction, for example, guide-
line development and PE agency establishment. Each country has
established more than one committee that is responsible for drug
reimbursement decision-making. Basically, pharmaceutical com-
panies are asked to submit clinical, safety, price, and PE evidence.
Thailand and South Korea have a specific agency to support PE
evidence. All the three countries have similar decision-making
criteria, even though those in Thailand and South Korea seem to
be more explicit in the case of PE. China and South Korea also
consider drug prices in other countries. China designs its drug
reimbursement lists tomatch both national and local needs, while
both Thailand and South Korea have a drug reimbursement list
only at the national level. Apparently, PE gradually plays impor-
tant roles in the efficiency of drug reimbursement decision-
making. Similar to many countries in the Asia-Pacific region,
the number of PE scientists is one of the major barriers for
adopting PE in the reimbursement decision-making. It also
leads to other barriers, including the controversial issues of
cost-effective threshold and the availability of relevant data,
which still require future improvements.
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